PSNL (PSNL)
Quantitative Summary
DeterministicFinancial health is average: Piotroski 4/9, Altman Z 2.8. Beneish M-Score of -0.83 exceeds the -2.22 academic threshold — earnings quality may warrant further review.
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Algorithmic Teardown
AI-GeneratedThe fundamental economics of PSNL reveal a severe value destruction mechanism, characterized by an ROIC-WACC spread of -39.3%, indicating capital allocation that significantly erodes shareholder value relative to the cost of equity. This negative return on invested capital is driven primarily by catastrophic net margins of -116.7% despite maintaining gross margins at 22.7%, a disparity suggesting operational inefficiencies or aggressive pricing pressures rather than pure input cost issues. The DuPont decomposition confirms that while asset turnover remains modest at 0.21x and leverage sits near parity with equity, the margin collapse is the primary driver of a -31.1% ROE. Although the Altman Z-Score of 2.8 suggests a moderate distance from bankruptcy distress and the Beneish M-Score of -0.83 indicates low earnings manipulation risk, the Piotroski F-Score of 4/9 reflects weak financial health relative to peers.
Valuation metrics are currently detached from traditional fundamental anchors due to the persistent loss-making trajectory, with revenue contracting at a rate of -17.7% year-over-year. While specific multiples like P/E or DCF fair value figures were not provided in the dataset, the market appears to be pricing in continued operational distress rather than sustainable growth, given the deep negative spread between returns and capital costs. The company's financial profile exhibits distinct factor tilts: it carries a significant Growth tilt with a Value Factor (HML) of -0.851 yet simultaneously displays severely Weak Profitability with an RMW score of -2.175. This creates a conflicting signal where the stock behaves like a high-growth name in terms of valuation expectations but fundamentally resembles a distressed value play, potentially leading to significant mean reversion risks if operational turnaround does not occur rapidly.
Risk assessment is further complicated by divergent signals between short-term momentum and long-term factor exposure. The annualized Fama-French Alpha stands at an exceptionally high 83.62%, suggesting the stock has recently decoupled from its historical risk factors, possibly due to temporary market dislocation or specific idiosyncratic events not captured in standard models. However, this momentum is counterbalanced by a net insider selling flow of $13,812 over the last 90 days, which often signals management caution regarding near-term prospects. The combination of negative profitability trends, shrinking revenues, and insider distribution creates an asymmetric risk profile where downside protection relies heavily on margin stabilization, while upside potential remains contingent on reversing the -39.3% spread between returns and capital costs.
Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.
Price Chart with Moving Averages
Quant Health Deep Dive
Profitability & Value Creation
DuPont Analysis — ROE Decomposition
Breaking down Return on Equity to see how the company generates its ROE — efficiency, margins, or leverage.
Balance Sheet Health
Insider Activity (Last 90 Days)
Open-market buys vs sells by company insiders. Source: yfinance.
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Risk Profile
Sharpe = risk-adjusted return (higher is better). Max drawdown = largest peak-to-trough decline. 1,200+ trading days.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fama-French 5-Factor Exposure
Academic factor model decomposition — what's really driving this stock's returns.
Fama-French 5-Factor Model. Data: Kenneth French Data Library. Regression over 3 years of daily returns.
Fundamentals
Passive Flow Attribution
ETF Draft EffectWhen investors buy or sell ETFs like ARKG or VHT, the fund manager is mechanically forced to buy or sell PSNL shares regardless of PSNL's individual fundamentals. We estimate $55M of passive capital is structurally linked to PSNL through 2 tracked ETFs. Passive flows have a limited but growing influence on PSNL's daily trading dynamics.
Passive exposure = Σ (ETF AUM × stock weight in ETF) across 2 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.
ETF Contagion Visualizer
Simulate a price drop in PSNL to visualize passive redemption contagion across ETFs and collateral stocks.
If PSNL (PSNL) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies Eli Lilly & Co. (LLY) as the most exposed collateral stock, sharing 1 ETFs with PSNL. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.
Contagion model based on shared ETF exposure and constituent weights across 2 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.
PSNL Ownership Dynamics
Passive funds hold 1 in every 14 PSNL shares, reducing daily market volatility.
PSNL (PSNL) exerts measurable gravity on the passive index market, currently representing 5.3% of the ARK Genomic Revolution ETF (ARKG) and 0.0% of the VHT (VHT). Across 3 tracked ETFs, approximately 8M shares (7.3% of float) are held by passive funds and rarely trade on the open market. As passive ownership grows, index inclusion changes may increasingly drive price discovery.
ETFs with Highest PSNL Exposure
Float lock-up computed from 3 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).
PSNL Institutional Volume Profile
252-day volume distribution by price level. The Point of Control (POC) marks — the price where the most institutional volume transacted — an implicit support/resistance floor.
The highest-volume price zone for PSNL over the past year sits near $6.44 (13% of 252-day volume). The current price of $11.14 trades 73.0% above this institutional floor — a sign of upside momentum, though a pullback to the POC zone is a common reversion target. The highly concentrated volume profile (13% at POC) indicates strong consensus on fair value — institutional participants have repeatedly transacted near this price.
Volume Profile computed from 252 trading days of OHLCV data. Volume allocated to price bins proportionally based on daily high-low range. Not investment advice.
Fails-to-Deliver (FTD) History
SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.
| Date | Failed Shares | Close Price | Notional Value |
|---|---|---|---|
| 2026-05-12 | 672 | $5.78 | $3,884.16 |
| 2026-05-04 | 28,137 | $5.78 | $162,631.86 |
| 2026-04-23 | 6,832 | $6.31 | $43,109.92 |
| 2026-04-22 | 3 | $6.24 | $18.72 |
| 2026-04-14 | 2,864 | $6.31 | $18,071.84 |
| 2026-04-10 | 1,620 | $6.09 | $9,865.8 |
| 2026-03-30 | 2,502 | $6.34 | $15,862.68 |
| 2026-03-26 | 1,180 | $7.70 | $9,086 |
| 2026-03-25 | 4,261 | $7.78 | $33,150.58 |
| 2026-03-23 | 2,224 | $7.26 | $16,146.24 |
| 2026-03-20 | 414 | $7.19 | $2,976.66 |
| 2026-03-19 | 83,286 | $6.96 | $579,670.56 |
| 2026-03-18 | 17,256 | $7.12 | $122,862.72 |
| 2026-03-11 | 609 | $8.31 | $5,060.79 |
| 2026-03-10 | 32,249 | $8.16 | $263,151.84 |
| 2026-03-05 | 9,185 | $8.93 | $82,022.05 |
| 2026-03-04 | 4,911 | $8.67 | $42,578.37 |
| 2026-03-03 | 17,075 | $9.06 | $154,699.5 |
| 2026-02-19 | 16,812 | $9.00 | $151,308 |
| 2026-02-12 | 3,138 | $8.90 | $27,928.2 |
| 2026-02-09 | 17,919 | $8.06 | $144,427.14 |
| 2026-02-06 | 2,028 | $7.42 | $15,047.76 |
| 2026-02-02 | 1,542 | $9.37 | $14,448.54 |
| 2026-01-30 | 3,525 | $9.97 | $35,144.25 |
| 2026-01-29 | 476 | $9.99 | $4,755.24 |
| 2026-01-23 | 2,421 | $11.25 | $27,236.25 |
| 2026-01-22 | 320 | $9.65 | $3,088 |
| 2026-01-21 | 2,710 | $9.39 | $25,446.9 |
| 2026-01-20 | 9 | $9.89 | $89.01 |
| 2026-01-16 | 18,443 | $9.61 | $177,237.23 |
Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.
Price Correlations
Statistical correlation of daily returns with other stocks. High correlations indicate stocks that move together; negative correlations can offer diversification.
| Peer | 252-Day (1Y) | 126-Day (6M) | Direction |
|---|---|---|---|
| WTGXX | NaN | NaN | |
| TEM | 0.544 | 0.532 | Moderate |
| ROK | 0.521 | 0.447 | Moderate |
| TXG | 0.496 | 0.524 | Moderate |
| PACB | 0.491 | 0.554 | Moderate |
| TWST | 0.471 | 0.492 | Moderate |
| ADPT | 0.441 | 0.533 | Moderate |
| NTRA | 0.435 | 0.451 | Moderate |
| EMR | 0.432 | 0.379 | Moderate |
| ABSI | 0.413 | 0.443 | Moderate |
Pearson correlation of daily log returns. 252d ≈ 1 trading year. Computed from price history. Not investment advice.
Compare PSNL to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: 2026-06-02.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.